Sirolimus 2% ( DrugBank: Sirolimus )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
36	表皮水疱症	2
192	コケイン症候群	2

36. 表皮水疱症

---

臨床試験数 : 160 /  薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States
2	NCT03016715 (ClinicalTrials.gov)	May 2016	9/1/2017	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus 2%;Drug: Vehicle	Premier Specialists, Australia	NULL	Recruiting	5 Years	N/A	All	8	Phase 2	Australia

192. コケイン症候群

---

臨床試験数 : 4 /  薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03016715 (ClinicalTrials.gov)	May 2016	9/1/2017	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus 2%;Drug: Vehicle	Premier Specialists, Australia	NULL	Recruiting	5 Years	N/A	All	8	Phase 2	Australia
2	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States